A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial

References

• Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-helicobacter pylori therapy. World J Gastroenterol. 2011;17:3971–3975. doi:10.3748/wjg.v17.i35.397122046084
   PubMed Web of Science ®Google Scholar
• Rimbara E, Fischbach LA, Graham DY. Optimal therapy for helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011;8:79–88. doi:10.1038/nrgastro.2010.21021293508
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. doi:10.1136/gut.2009.19275720525969
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a metaanalytical perspective. Helicobacter. 2007;12:50–58. doi:10.1111/j.1523-5378.2007.00576.x17991177
   PubMed Web of Science ®Google Scholar
• Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol. 2004;10:668–671. doi:10.3748/wjg.v10.i5.66814991935
   PubMed Web of Science ®Google Scholar
• Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy sing omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther. 1998;12:383–388. doi:10.1046/j.1365-2036.1998.00315.x9690730
   PubMed Web of Science ®Google Scholar
• Chuah SK, Liang CM, Lee CH, et al. A randomized control trial comparing two levofloxacin-containing second-line therapies for Helicobacter pylori eradication. Medicine (Baltimore). 2016;95:e3586. doi:10.1097/MD.000000000000486427175657
   PubMed Web of Science ®Google Scholar
• Chuah SK, Tai WC, Lee HC, Liang CM. Quinolone-containing therapies in the eradication of Helicobacter pylori. Biomed Res Int. 2014;2014:151543. doi:10.1155/2014/15154325243116
   PubMed Web of Science ®Google Scholar
• Chuah SK, Hsu PI, Chang KC, et al. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter. 2012;17:216–223. doi:10.1111/j.1523-5378.2012.00937.x22515360
   PubMed Web of Science ®Google Scholar
• Chuah SK, Tai WC, Hsu PI, et al. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-days levofloxacin/amoxicillin/protonpump inhibitors -a pilot study. Helicobacter. 2012;17:374–381. doi:10.1111/j.1523-5378.2012.00960.x22967121
   PubMed Web of Science ®Google Scholar
• Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53:1374–1384. doi:10.1136/gut.2003.02211115306603
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409–414.21188333
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008;68:725–736. doi:10.2165/00003495-200868060-0000118416582
   PubMed Web of Science ®Google Scholar
• Tai WC, Liang CM, Lee CH, et al. Seven-day non-bismuth containing quadruple therapy could achieve a grade “A” success rate for first-line. Helicobacter Pylori Eradication Biomed Res Int. 2015;2015:623732.26090428
   PubMed Web of Science ®Google Scholar
• Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori Infection. Clin Gastroenterol Hepatol. 2010;8:36–41. doi:10.1016/j.cgh.2009.09.03019804842
   PubMed Web of Science ®Google Scholar
• Ren L, Lu H, Li HY, et al. New dual therapy for primary treatment of Helicobacter pylori infection: a prospective randomized study in Shanghai, China. J Dig Dis. 2014;15:622–627. doi:10.1111/1751-2980.1218625205201
   PubMed Web of Science ®Google Scholar
• Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895–905. doi:10.1016/j.cgh.2014.10.03625460556
   PubMed Web of Science ®Google Scholar
• Zullo A, Ridola L, Francesco VD, et al. High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Ann Gastroenterol. 2015;28:448–451.26423014
   PubMed Web of Science ®Google Scholar
• Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;1(74):1718–1724. doi:10.1093/jac/dkz046
   Web of Science ®Google Scholar
• Mori H, Suzuki H. Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. J Neurogastroenterol Motil. 2019;25:6–14. doi:10.5056/jnm1813930504527
   PubMed Web of Science ®Google Scholar
• Masaoka T, Kameyama H, Yamane T, et al. Pathophysiology of potassium-competitive acid blocker-refractory gastroesophageal reflux and the potential of potassium-competitive acid blocker test. J Neurogastroenterol Motil. 2018;24:577–583. doi:10.5056/jnm1803630347936
   PubMed Web of Science ®Google Scholar
• Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther. 2019;49:140–146. doi:10.1111/apt.1506230589965
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Yamaoka Y. Role of vonoprazan in helicobacter pylori eradication therapy in Japan. Front Pharmacol. 2018;9:1560. doi:10.3389/fphar.2018.0156030697158
   PubMed Web of Science ®Google Scholar
• Abadi ATB, Ierardi E. Vonoprazan and helicobacter pylori treatment: a lesson from Japan or a limited geographic phenomenon? Front Pharmacol. 2019;10:316. doi:10.3389/fphar.2019.0084831024299
   PubMed Web of Science ®Google Scholar
• Katsuki H, Yagi H, Arimori K, et al. Determination of R (+)- and S (-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996;13:611–615. doi:10.1023/A:10160625085808710755
   PubMed Web of Science ®Google Scholar
• Metz DC, Howden CW, Perez MC, Larsen L, O’Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29:742–754. doi:10.1111/j.1365-2036.2009.03954.x19210298
   PubMed Web of Science ®Google Scholar
• Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25:627–638. doi:10.1185/0300799080269388319232037
   PubMed Web of Science ®Google Scholar
• Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: a randomized study in Japan. World J Gastrointest Pharmacol Ther. 2012;3:1–6. doi:10.4292/wjgpt.v3.i1.122408744
   PubMedGoogle Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51–69. doi:10.1053/j.gastro.2016.04.00627102658
   PubMed Web of Science ®Google Scholar
• Chiang HH, Wu DC, Hsu PI, et al. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. Drug Des Devel Ther. 2019;13:1347–1356. doi:10.2147/DDDT.S193559
   PubMed Web of Science ®Google Scholar
• Kukulka M, Eisenberg C, Nudurupati S. Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg. Clin Exp Gastroenterol. 2011;4:213–220. doi:10.2147/CEG.S2406322016582
   PubMedGoogle Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275–278. doi:10.1111/j.1523-5378.2007.00518.x17669098
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved. Drugs. 2008;68:725–736. doi:10.2165/00003495-200868060-0000118416582
   PubMed Web of Science ®Google Scholar